
|Videos|April 6, 2016
How Renal Function and Comorbidities Affect Dosing for NOACs
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient's renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
Advertisement
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient’s renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
2
Clinical Data Support Use of Low-Carbon Version of Albuterol Metered Dose Inhaler for Asthma
3
Hyperlipidemia Causally Linked to Increased Risk of Alzheimer Disease
4
Study Shows Growing Confidence in Cell and Gene Therapies Across the Care Continuum
5














































































































































































































